vs
DIAMOND HILL INVESTMENT GROUP INC（DHIL）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
DIAMOND HILL INVESTMENT GROUP INC的季度营收约是REGENXBIO Inc.的1.2倍（$36.6M vs $30.3M），DIAMOND HILL INVESTMENT GROUP INC净利率更高（25.3% vs -221.3%，领先246.7%），REGENXBIO Inc.同比增速更快（43.0% vs -6.6%），DIAMOND HILL INVESTMENT GROUP INC自由现金流更多（$-9.1M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 0.4%）
钻石棒球控股（DBH）是一家美国体育产权持有与运营集团，在美国和加拿大拥有并运营超过40支小联盟棒球队。该公司由媒体集团奋进集团于2021年成立，目前是投资机构银湖旗下的子公司，专注于北美小联盟棒球产业的运营与发展。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
DHIL vs RGNX — 直观对比
营收规模更大
DHIL
是对方的1.2倍
$30.3M
营收增速更快
RGNX
高出49.6%
-6.6%
净利率更高
DHIL
高出246.7%
-221.3%
自由现金流更多
DHIL
多$43.7M
$-52.8M
两年增速更快
RGNX
近两年复合增速
0.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $36.6M | $30.3M |
| 净利润 | $9.3M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | 16.9% | -190.0% |
| 净利率 | 25.3% | -221.3% |
| 营收同比 | -6.6% | 43.0% |
| 净利润同比 | 25.3% | -31.2% |
| 每股收益（稀释后） | $3.42 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DHILRGNX
| Q4 25 | $36.6M | $30.3M | ||
| Q3 25 | $37.4M | $29.7M | ||
| Q2 25 | $36.0M | $21.4M | ||
| Q1 25 | $37.1M | $89.0M | ||
| Q4 24 | $39.1M | $21.2M | ||
| Q3 24 | $39.0M | $24.2M | ||
| Q2 24 | $36.7M | $22.3M | ||
| Q1 24 | $36.3M | $15.6M |
净利润DHILRGNX
| Q4 25 | $9.3M | $-67.1M | ||
| Q3 25 | $13.6M | $-61.9M | ||
| Q2 25 | $15.6M | $-70.9M | ||
| Q1 25 | $10.4M | $6.1M | ||
| Q4 24 | $7.4M | $-51.2M | ||
| Q3 24 | $14.6M | $-59.6M | ||
| Q2 24 | $8.1M | $-53.0M | ||
| Q1 24 | $13.0M | $-63.3M |
毛利率DHILRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率DHILRGNX
| Q4 25 | 16.9% | -190.0% | ||
| Q3 25 | 26.0% | -176.3% | ||
| Q2 25 | 21.6% | -296.3% | ||
| Q1 25 | 35.2% | 13.6% | ||
| Q4 24 | 33.8% | -242.1% | ||
| Q3 24 | 26.2% | -256.6% | ||
| Q2 24 | 33.1% | -251.3% | ||
| Q1 24 | 22.9% | -408.8% |
净利率DHILRGNX
| Q4 25 | 25.3% | -221.3% | ||
| Q3 25 | 36.2% | -208.3% | ||
| Q2 25 | 43.2% | -331.8% | ||
| Q1 25 | 27.9% | 6.8% | ||
| Q4 24 | 18.9% | -241.3% | ||
| Q3 24 | 37.5% | -246.3% | ||
| Q2 24 | 22.2% | -237.7% | ||
| Q1 24 | 35.9% | -405.4% |
每股收益（稀释后）DHILRGNX
| Q4 25 | $3.42 | $-1.30 | ||
| Q3 25 | $4.99 | $-1.20 | ||
| Q2 25 | $5.73 | $-1.38 | ||
| Q1 25 | $3.77 | $0.12 | ||
| Q4 24 | $2.76 | $-0.99 | ||
| Q3 24 | $5.35 | $-1.17 | ||
| Q2 24 | $2.93 | $-1.05 | ||
| Q1 24 | $4.62 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $176.4M | $102.7M |
| 总资产 | $260.4M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DHILRGNX
| Q4 25 | — | $230.1M | ||
| Q3 25 | — | $274.2M | ||
| Q2 25 | — | $323.3M | ||
| Q1 25 | — | $267.9M | ||
| Q4 24 | $41.6M | $234.7M | ||
| Q3 24 | — | $255.5M | ||
| Q2 24 | — | $290.4M | ||
| Q1 24 | — | $338.7M |
股东权益DHILRGNX
| Q4 25 | $176.4M | $102.7M | ||
| Q3 25 | $180.9M | $161.5M | ||
| Q2 25 | $171.6M | $213.7M | ||
| Q1 25 | $168.6M | $274.2M | ||
| Q4 24 | $162.3M | $259.7M | ||
| Q3 24 | $166.5M | $301.4M | ||
| Q2 24 | $156.5M | $348.3M | ||
| Q1 24 | $158.3M | $390.7M |
总资产DHILRGNX
| Q4 25 | $260.4M | $453.0M | ||
| Q3 25 | $256.3M | $525.2M | ||
| Q2 25 | $261.0M | $581.0M | ||
| Q1 25 | $224.4M | $490.9M | ||
| Q4 24 | $245.1M | $466.0M | ||
| Q3 24 | $240.8M | $519.1M | ||
| Q2 24 | $213.1M | $569.4M | ||
| Q1 24 | $209.1M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-6.6M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-9.1M | $-52.8M |
| 自由现金流率自由现金流/营收 | -24.8% | -174.0% |
| 资本支出强度资本支出/营收 | 6.7% | 1.7% |
| 现金转化率经营现金流/净利润 | -0.71× | — |
| 过去12个月自由现金流最近4个季度 | $-34.3M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流DHILRGNX
| Q4 25 | $-6.6M | $-52.3M | ||
| Q3 25 | $-7.7M | $-56.0M | ||
| Q2 25 | $-5.0M | $-49.3M | ||
| Q1 25 | $-10.7M | $33.6M | ||
| Q4 24 | $16.6M | $-31.6M | ||
| Q3 24 | $18.5M | $-40.5M | ||
| Q2 24 | $19.2M | $-45.5M | ||
| Q1 24 | $-12.3M | $-55.5M |
自由现金流DHILRGNX
| Q4 25 | $-9.1M | $-52.8M | ||
| Q3 25 | $-8.3M | $-56.5M | ||
| Q2 25 | $-5.7M | $-49.7M | ||
| Q1 25 | $-11.3M | $32.6M | ||
| Q4 24 | $15.2M | $-32.7M | ||
| Q3 24 | $18.3M | $-40.9M | ||
| Q2 24 | $19.2M | $-46.0M | ||
| Q1 24 | $-12.4M | $-56.0M |
自由现金流率DHILRGNX
| Q4 25 | -24.8% | -174.0% | ||
| Q3 25 | -22.2% | -189.9% | ||
| Q2 25 | -15.8% | -232.8% | ||
| Q1 25 | -30.4% | 36.6% | ||
| Q4 24 | 38.9% | -154.2% | ||
| Q3 24 | 46.8% | -168.9% | ||
| Q2 24 | 52.4% | -206.2% | ||
| Q1 24 | -34.2% | -358.5% |
资本支出强度DHILRGNX
| Q4 25 | 6.7% | 1.7% | ||
| Q3 25 | 1.6% | 1.7% | ||
| Q2 25 | 2.0% | 1.8% | ||
| Q1 25 | 1.5% | 1.2% | ||
| Q4 24 | 3.5% | 5.1% | ||
| Q3 24 | 0.7% | 1.3% | ||
| Q2 24 | 0.0% | 2.1% | ||
| Q1 24 | 0.4% | 3.6% |
现金转化率DHILRGNX
| Q4 25 | -0.71× | — | ||
| Q3 25 | -0.57× | — | ||
| Q2 25 | -0.32× | — | ||
| Q1 25 | -1.04× | 5.53× | ||
| Q4 24 | 2.25× | — | ||
| Q3 24 | 1.26× | — | ||
| Q2 24 | 2.36× | — | ||
| Q1 24 | -0.94× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DHIL
| Proprietary Funds | $26.0M | 71% |
| Separately Managed Accounts | $5.0M | 14% |
| Other Pooled Vehicles | $2.8M | 8% |
| Administration Revenuenetofrelatedexpense | $1.7M | 5% |
| Collective Investment Trusts | $1.4M | 4% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
